PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

PTC Therapeutics, Inc.

Overview
Date Founded

1998

Headquarters

100 Corporate Court, South Plainfield, NJ, 07080, USA

Type of Company

Public

Employees (Worldwide)

761

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Contact Data
Trying to get in touch with decision makers at PTC Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Financial Officer & Treasurer

Chief Development Officer

Senior Vice President, Finance & Chief Accounting Officer

Chief Business Officer

Chief Technical Operations Officer

Chief Legal Officer & Executive Vice President

General Manager & Head-Medical Affairs, Europe

Benefit Plan Administrator

Board of Directors

Professor at Yale University

Co-Founder at PTC Therapeutics, Inc.

Director, Chief Medical Officer, Viralclear Pharmaceuticals, Inc at BioSig Technologies, Inc.

Founder at PTC Therapeutics, Inc.

Former President-Europe & Canada Region at Merck & Co., Inc.

Executive Advisor at LRVHealth Ventures LLC

Chief Executive Officer & Director at TScan Therapeutics, Inc.

Chief Financial Officer at Constellation Pharmaceuticals, Inc.

Former GM-Rare Disease Business Unit & Senior Vice President at Genzyme Corp.

Paths to PTC Therapeutics, Inc.
Potential Connections via
Relationship Science
You
PTC Therapeutics, Inc.
Owners & Shareholders
Details Hidden

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges. The firm’s research process will be focused on a scientific approach to assessing and accurately defining the fundamental value of outcomes surrounding transformational events in the lifecycle of healthcare companies.

Details Hidden

TimesSquare is a fundamental research-oriented, growth equity investment management firm that specializes in Small-Cap, Small/Mid-Cap, Mid-Cap, and concentrated growth equity strategies. The firm seeks build diversified portfolios of growth stocks that generate excellent risk-adjusted returns. Proprietary fundamental research drives their disciplined, bottom-up process of selecting companies that meet their definition of a superior growth business. Each of their investment strategies is managed by a portfolio manager or group of portfolio managers in a manner consistent with their approach to investing. In general, TimesSquare looks for a targeted range of price appreciation potential generally over a 12 to 18 month investment horizon. The firm may also consider the probability of retaining/widening margins, proportion of recurring revenues, strength of balance sheet, barriers to entry and competitive landscape, management track record, and market visibility.

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Recent Transactions
Details Hidden

PTC Therapeutics, Inc. purchases Censa Pharmaceuticals, Inc.

Details Hidden

PTC Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

PTC Therapeutics, Inc. issued . USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onPTC Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onPTC Therapeutics, Inc. issued . USD Common Stock

Underwriter

Advised onPTC Therapeutics, Inc. issued USD Common Stock

Co-Chair, Capital Markets Group

Advised onPTC Therapeutics, Inc. issued USD Common Stock

Managing Director

Advised onPTC Therapeutics, Inc. issued . USD Common Stock

Director

Advised onPTC Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Consultant

Senior Advisor at Warburg Pincus LLC

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2019
Market Capitalization
$4.61B
Total Enterprise Value
$2.47B
Earnings Per Share
$-4.27
Debt TEV
0.13x
TEVNet Income
-9.81x
Enterprise Value / Sales
8.04x
Total Equity
$594M
Total Debt
$328M
EBITDAMargin
-51.06%
EBITDA
$-157M
Net Profit
$-252M
Revenue
$307M
Five Year Compounded Annual Growth Rate Of Revenue
64.81%
Three Year Compounded Annual Growth Rate Of Revenue
54.83%
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Investors
Details Hidden

ACM manages the Adage Capital Partners Fund (ACP). The firm seeks to achieve its objective through stock selection based primarily on intra-industry fundamental analysis with a dedicated focus on intra-industry valuation methodologies. Primary research is a central component of their investment process. ACM utilizes a staff of portfolio managers and equity analysts dedicated to tracking specific sectors represented within the Index that utilize a stock valuation methodology designed for each specific sector in selecting the investments of ACP. The firm currently utilizes one non-industry specific analyst, focusing on risk arbitrage opportunities for ACP. They may employ additional analysts and/or portfolio managers in the future, focusing on non-industry specific methodologies for identifying investments for ACP, and in connection with such methodologies ACM may cause ACP engage in additional types of investments, such as leveraged trading and/or risk arbitrage or other event driven trading.

Details Hidden

Bay City Capital invests in both private and public life sciences companies located in the US. The firm targets companies operating in the fields of biopharmaceuticals, drug discovery, medical devices and diagnostics. They acts as lead/co-lead investor and provides financing for seed, early and later stage capital requirements. They takes a seat on the board of directors and makes co-investments.

Details Hidden

Vulcan ventures Inc seeks investment opportunities in companies located in the US. The firm focuses on companies with an experienced management team, recurring revenues and substantial free cash flows. It targets companies operating in the fields of media conglomerates, energy minerals, financial services, healthcare services, life science and communication. It provides financing for early stage capital requirements.

Suppliers
Faes Farma SA Pharmaceuticals | Leioa, Spain

Faes Farma SA is a pharmaceutical company. It engages in manufacturing and sale of chemical and pharmaceutical products, as well as the acquisition, purchase, sale, investment, holding, administration, management, negotiation and leasing of companies, of transferable and immovable securities, patents, trademarks and registrations and social participations. The company was founded in 1993 and is headquartered in Leioa, Spain.

Ionis Pharmaceuticals, Inc. Medical Support Services | Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Akcea Therapeutics, Inc. Pharmaceuticals | Boston, MA

Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.

Competitors
Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Biogen, Inc. Biotechnology - Canyon Country, CA

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by PTC Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of PTC Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and PTC Therapeutics, Inc..